Filana Therapeutics adds industry veteran Jill M. Quigley to its board as the company prepares for a Phase 2a clinical trial of simufilam in TSC-related epilepsy, expected to begin screening in Q1 2027.
The appointment of Jill M. Quigley to the board adds executive and financing experience but contains no hard financial facts: no figures, no guidance change, no trial results. The only forward-looking detail is patient screening for the Phase 2a simufilam study in TSC-related epilepsy expected to begin by Q1 2027, which was already the company's plan. Routine governance news, unlikely to move the stock materially.
Filana Therapeutics, Inc. has appointed Jill M. Quigley to its Board of Directors to bolster its leadership in drug development and financing. Quigley brings over 20 years of industry experience, including previous roles at Passage Bio and Terns Pharmaceuticals. The company is currently preparing for a Phase 2a clinical study of simufilam for TSC-related epilepsy, with patient screening scheduled to commence by the first quarter of 2027.
Patient screening for the planned Phase 2a clinical study of simufilam in TSC-related epilepsy is expected to begin by the first quarter of 2027.